Concord Drugs Ltd. Concord Drugs Limited is a pharmaceutical company. The Company is engaged in the manufacture of pharmaceutical formulations and the trading of packing material. It offers various products and services, such as finished pharmaceutical formulations, which includes Injectables (Small volume parenterals and Dry powders), Tissue Bio-Adhesive, Tablets, Capsules, and Ready-to-Fill Pellets. Its pellets are categorized as gastrointestinal drug pellets; anti-cholesterol drug pellets; cardiovascular drug pellets; respiratory drug pellets; pain management drug pellets; anti-obesity drug pellets; anti-depressant drug pellets; central nervous system drug pellets; urological drug pellets; anti-microbial, anti-infective and adjuvant drugs pellets; taste mask drug pellets/powder, and nutrition and food supplement drug pellets. Its injectables product list includes Tissue Bio Adhesive, Liquid injectables and Dry powder injections. Its products include Loperamide Tablets and Iso Amyl 2-Cyano Acrylate.
Ford US Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.